Roivant Sciences Stock-Based Comp decreased by 26.5% to $77.17M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 7.6%, from $83.49M to $77.17M. Over 4 years (FY 2021 to FY 2025), Stock-Based Comp shows a downward trend with a -11.5% CAGR.
Increasing levels may indicate a focus on talent retention but can also signal potential shareholder dilution.
This represents the value of equity-based awards granted to employees as part of their total compensation package. Since...
Standard across large-cap corporations; varies based on corporate compensation philosophy.
stock_based_compensation| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $19.27M | $397.31M | $71.22M | $77.16M | $72.79M | $61.98M | $57.73M | $25.28M | $49.26M | $49.32M | $54.33M | $46.72M | $50.19M | $71.67M | $83.68M | $83.49M | $82.18M | $81.82M | $105.00M | $77.17M |
| QoQ Change | — | >999% | -82.1% | +8.3% | -5.7% | -14.9% | -6.9% | -56.2% | +94.9% | +0.1% | +10.2% | -14.0% | +7.4% | +42.8% | +16.8% | -0.2% | -1.6% | -0.4% | +28.3% | -26.5% |
| YoY Change | — | — | — | — | +277.8% | -84.4% | -18.9% | -67.2% | -32.3% | -20.4% | -5.9% | +84.8% | +1.9% | +45.3% | +54.0% | +78.7% | +63.7% | +14.2% | +25.5% | -7.6% |
| Segment | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|
| Reportable Segment | $70.83M | $86.87M | $69.52M |
| Total | $81.82M | $105.00M | $77.17M |